More is Possible
We’re creating a future where biotechnologies deliver more opportunities in Human Health.
Biotechnologies that unlock true potential.
Every day is an opportunity to improve and evolve. We’re harnessing the power of a unique drug delivery technology, TPM®, to create, enhance and differentiate proven products across Human Health.
Introducing TPM® – The only drug delivery platform based on tocopheryl phosphate, an enhanced form of Vitamin E.
World-first innovation, over fifteen years in the making. Formulations containing our proprietary TPM® have been proven to enhance the delivery, effectiveness, and/or tolerability of a wide range of proven products covering a spectrum of applications.
Phase III insomnia clinical trial
Avecho is progressing a pivotal Phase III study of an oral cannabidiol therapy for insomnia. The program targets the global insomnia market, supported by the differentiated profile of the proprietary TPM®-enhanced soft-gel capsule.
Positive interim analysis supports continuation of Phase III insomnia trial
Avecho has announced the planned interim analysis supports continuation of its pivotal Phase III trial of its TPM®-enhanced cannabidiol soft-gel capsule for insomnia.
